Advancements in adoptive cell therapy over the last four decades have revealed various
new therapeutic strategies, such as chimeric antigen receptors (CARs), which are dedicated …

Equipping cancer-fighting immune cells with chimeric antigen receptor (CAR) has gained
immense attention for cancer treatment. CAR-engineered T cells (CAR T cells) are the first …

In the last decade, Chimeric Antigen Receptor (CAR)-T cell therapy has emerged as a
promising immunotherapeutic approach to fight cancers. This approach consists of …

Simple Summary Chimeric antigen receptor T cells (CAR T-cells) are engineered T cells that
target tumor-associated antigens. CAR T-cell therapy is a novel developed immunotherapy …

Adoptive cell treatment (ACT) utilizing chimeric antigen receptors (CAR) diverts the
specificity of safe cells against a target-specific antigen and portrays exceptional potential for …

Chimeric antigen receptor (CAR)-T cell therapy has led to remarkable clinical outcomes in
the treatment of hematological malignancies. However, challenges remain, such as limited …

Recent reports on the impressive efficacy of chimeric antigen receptor (CAR)-modified T
cells against hematologic malignancies have inspired oncologists to extend these efforts for …

Simple Summary New approaches in adoptive immunotherapy using chimeric antigen
receptor (CAR)-modified cells have been developing very quickly in recent years, entering …

Adoptive cell therapy has received a great deal of interest in the treatment of advanced
cancers that are resistant to traditional therapy. The tremendous success of chimeric antigen …

Chimeric antigen receptor (CAR)-engineered T lymphocytes (CAR Ts) produced impressive
clinical results against selected hematological malignancies, but the extension of CAR T cell …